The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1452-1458

  Ji, Yan ^a   Lee, Hong Jin ^a   Goodman, Catherine ^a   Uskokovic, Milan ^a   Liby, Karen ^b   Sporn, Michael ^b   Suh, Nanjoo ^a  

^a RUTGERS UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 22 OXACALCITRIOL; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; CALCITRIOL; CCAAT ENHANCER BINDING PROTEIN BETA; CD14 ANTIGEN; ESTERASE; IMIDAZOLE DERIVATIVE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NOGGIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRITERPENOID;

ARTICLE; CARTILAGE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; MYELOID LEUKEMIA; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

BONE MORPHOGENETIC PROTEINS; CALCITRIOL; CARRIER PROTEINS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL DIFFERENTIATION; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HL-60 CELLS; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; OLEANOLIC ACID; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 33746038942     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0136     Document Type: Article

References (42)

1. Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002;191:1-16.
2. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
3. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63.
4. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
5. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
6. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
7. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-93.
8. Chen T, Jackson CR, Link A, et al. Int7G24A variant of transforming growth factor-β receptor type I is associated with invasive breast cancer. Clin Cancer Res 2006;12:392-7.
9. Rooke HM, Vitas MR, Crosier PS, Crosier KE. The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999;13:535-41.
10. Falk LA, De Benedetti F, Lohrey N, et al. Induction of transforming growth factor-β1 (TGF-β1), receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: possible TGF-β 1-mediated autocrine inhibition. Blood 1991;77:1248-55.
11. Koli K, Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 1995;55:1540-6.
12. Wu G, Fan RS, Li W, Srinivas V, Brattain MG. Regulation of transforming growth factor-β type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. J Biol Chem 1998;273:7749-56.
13. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317-21.
14. Suh N, Roberts AB, Birkey Reffey S, et al. Synthetic triterpenoids enhance transforming growth factor β/Smad signaling. Cancer Res 2003;63:1371-6.
15. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer. Cancer Res 2004;64:3566-71.
16. Nishino H, Nishino A, Takayasu J, et al. Inhibition of the tumorpromoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res 1988;48:5210-5.
17. Huang MT, Ho CT, Wang ZY, et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 1994;54:701-8.
18. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma 2004;51:327-33.
19. Suh N, Honda T, Finlay HJ, et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res 1998;58:717-23.
20. Suh N, Wang Y, Honda T, et al, A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999;59:336-41.
21. Place AE, Suh N, Williams CR, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9:2798-806.
22. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979;54:713-33.
23. Studzinski GP, Reddy KB, Hill HZ, Bhandal AK. Potentiation of 1-β-d-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res 1991;51:3451-5.
24. Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99:326-35.
25. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 2001;80:471-82.
26. Ji Y, Kutner A, Verstuyf A, Verlinden L, Studzinski GP. Derivatives of vitamins D2 and D3 activate three MAPK pathways and up-regulate pRb expression in differentiating HL60 cells. Cell Cycle 2002;1:410-5.
27. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 2005;19:1350-4.
28. Ji Y, Studzinski GP. Retinoblastoma protein and CCAAT/enhancer-binding protein β are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res 2004;64:370-7.
29. Pan Z, Hetherington CJ, Zhang DE. CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor β signaling in monocyte development. J Biol Chem 1999;274:23242-8.
30. Studzinski GP, Wang X, Ji Y, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005;97:47-55.
31. Konopleva M, Tsao T, Estrov Z, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 2004;64:7927-35.
32. Samudio I, Konopleva M, Hail N, Jr., et al. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 2005;280:36273-82.
33. Ikeda T, Kimura F, Nakata Y, et al. Triterpenoid CDDO-Im down-regulates PML/RARα expression in acute promyelocytic leukemia cells. Cell Death Differ 2005;12:523-31.
34. Cao Z, Flanders KC, Bertolette D, et al. Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-β and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 2003;101:498-507.
35. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: implications for carcinogenesis. Oncogene 2005;24:5742-50.
36. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J Biol Chem 1999;274:37413-20.
37. Yu L, Hebert MC, Zhang YE. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 2002;21:3749-59.
38. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 1999;13:804-16.
39. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-β-dependent responses in human mesangial cells. FASEB J 2003;17:1576-8.
40. Wang Q, Wang X, Studzinski GP. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3. J Cell Biochem 2003;89:1087-101.
41. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005;19:1812-7.
42. Reddi AH, editor. Bone morphogenetic proteins. Cytokine Growth Factor Rev 2005;16:249-376.